IWC
FDMT icon

Integrated Wealth Concepts’s 4D Molecular Therapeutics FDMT Stock Holding History

Integrated Wealth Concepts’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227 Buy
+17
New +$166 ﹤0.01% 5742

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Integrated Wealth Concepts's FDMT Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 17 shares worth $227. The stake represents ﹤0.01% of the portfolio and ranks #5742 among its holdings.

158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Integrated Wealth Concepts held 17 shares of 4D Molecular Therapeutics worth $227 as of Q2 2026.
  • 4D Molecular Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #5742 holding.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.